Mepolizumab long-term remodeling effect in severe asthma responders: the MESILICO study.

Study limitation reported by the research below: “Findings are preliminary and limited to responders who tolerated and adhered to 3 years of treatment; generalizability to the broader severe asthma population is uncertain.”